High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

Amit K Mahajan, Gregory B Diette, Umur Hatipoğlu, Andrew Bilderback, Alana Ridge, Vanessa Walker Harris, Vijay Dalapathi, Sameer Badlani, Stephanie Lewis, Jeff T Charbeneau, Edward T Naureckas, Jerry A Krishnan, Amit K Mahajan, Gregory B Diette, Umur Hatipoğlu, Andrew Bilderback, Alana Ridge, Vanessa Walker Harris, Vijay Dalapathi, Sameer Badlani, Stephanie Lewis, Jeff T Charbeneau, Edward T Naureckas, Jerry A Krishnan

Abstract

Background: High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD).

Methods: Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments (minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced expired volume in 1 second.

Results: Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other secondary outcomes.

Conclusions: HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate the role of HFCWO in improving in-hospital and post-discharge outcomes in this population.

Trial registration: ClinicalTrials.gov: NCT00181285.

Figures

Figure 1
Figure 1
Flowchart of Study Cohort. N = 94 adults (age 18 years and older) admitted with a physician-diagnosis of acute asthma or COPD and with FEV1/FVC < 70% at the time of screening were assessed for eligibility. Fifty-two (55%) were randomized to active HFCWO (n = 25) or sham HFCWO (n = 27).

References

    1. Castro M, Zimmerman N, Crocker S. et al.Asthma intervention program prevents readmission in high healthcare utilizers. Am J Respir Crit Care Med. 2003;168:1094–1099.
    1. Bloomberg G, Trinkaus K, Fisher E Jr. et al.Hospital readmission for childhood asthma: A 10-year metropolitan study. Am J Respir Crit Care Med. 2003;167:1068–1076. doi: 10.1164/rccm.2201015.
    1. Rowe B, Bota G, Fabris L. et al.Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department. JAMA. 1999;281:2119–2126. doi: 10.1001/jama.281.22.2119.
    1. Niewoehner D, Erbland M, Deupree R. et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive lung disease. N Engl J Med. 1999;340:1941–1947. doi: 10.1056/NEJM199906243402502.
    1. Garcia-Aymerich J, Farrero E, Felez M. et al.Risk factors for readmission to hospital for a copd exacerbation: A prospective study. Thorax. 2003;58:100–105. doi: 10.1136/thorax.58.2.100.
    1. Mannino D, Homa D, Akinbami L, Ford E, Redd S. Chronic obstructive pulmonary disease surveillance - - - United States, 1971-2000. National Center of Health Statistics. 2002.
    1. Carroll N, Mutavdic S, James A. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002;47:5.
    1. Kuyper L, Pare P, Hogg J, Lambert R, Ionescu D, Woods R, Bai T. Characterization of airway plugging in fatal asthma. Am J Med. 2003;115:6–11.
    1. Tanizaki Y, Kitani H, Okazaki M, Mifune T, Mitsunobu F, Kimura I. Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in patients with bronchial asthma. J Asthma. 1993;30:5. doi: 10.3109/02770909309066375.
    1. Rogers D, Barnes P. Treatment of airway mucus hypersecretion. Annals of Medicine. 2006;38:9.
    1. Linhartova A, Anderson A, Foraker A. Intraluminal exudates of nonrespiratory bronchioles in pulmonary emphysema. Human Pathology. 1971;2:3.
    1. Arens R, Gozal D, Omlin K, Vega J, Boyd K, Keens T, Woo M. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1994;150:1154–1157.
    1. Fink J, Mahlmeister M. High-frequency oscillation of the airway and chest wall. Respir Care. 2002;47:797–807.
    1. Hansen L, Warwick W. High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol. 1990;24:289–294.
    1. Lange D, Lechtzin N, Davey C, David W, Heiman-Patteron T, Gelinas D, Becker B, Mitsumoto H. High-frequency chest wall oscillation in ALS: An exploratory randomized, controlled trial. Neurology. 2006;67:6. doi: 10.1212/01.wnl.0000229468.02136.f6.
    1. Morrison L, Agnew J. Oscillation devices for airway clearance in people with cystic fibrosis. Cochran Database of Systemic Reviews 2009. 2010. p. CD006842.
    1. Krishnan JA, Ridge A, Walker Harris V, Lewis S, Ivy S, Dalapathi V, Bilderback A, Mazurek A, Charbeneau J, Hatipoglu U, Badlani S, Diette G. Treating exacerbations of asthma or chronic obstructive pulmonary disease (COPD) with high frequency chest wall oscillation (HFCWO) in hospitalized patients (Abstract 3869) Eur Respir J. 2010. p. 690s. (accessed April 20, 2011)
    1. National Heart Lung; Blood Institute. Guidelines for the diagnosis and management of asthma (EPR-3) (accessed April 21, 2011)
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (accessed April 21, 2011)
    1. Ries AL. Minimally clinically important difference for the UCSD shortness of breath questionnaire, borg scale, and visual analog scale. COPD. 2005;2:105–110. doi: 10.1081/COPD-200050655.
    1. Sutherland ER. Sham procedure versus usual care as the control in clinical trials of devices. Proc Am Thorac. 2007;4:574–576. doi: 10.1513/pats.200707-090JK.
    1. Al-Mutairi S, Sharma P, Al-Alawi A, Al-Deen J. Impulse oscillometry: An alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. Clin Exp Med. 2007;7:8.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren